Post-trauma mortality increase at age 60: a cutoff for defining elderly? - 12/10/16
, Billy J. Moore, Ph.D. a, Tiffany L. Overton, M.A., M.P.H. a, Jessica Laureano Phillips, M.S., M.P.H. a, Kaley J. Simon, M.P.H., C.P.H. a, Rajesh R. Gandhi, M.D., Ph.D. b, Therese M. Duane, M.D., M.B.A. c, Shahid Shafi, M.D., M.P.H. aAbstract |
Background |
There has been an increasing emphasis on identifying elderly trauma patients. However, definitions based solely on age vary widely, ranging from age 55 to 80 years, hampering optimal trauma management for older patients. The goal of this study was to develop an objective, data-driven definition for “elderly” in trauma care by evaluating mortality risk as a function of age.
Methods |
We conducted a retrospective analysis of 872,861 adult (≥18 years) patients from the National Trauma Data Bank's National Sample Program from 2003 to 2010. The primary outcome was risk-adjusted in-hospital mortality determined using multivariate logistic regression. Contribution of age to mortality was investigated through step-wise regression and percent of R2 attributable to age. We searched for straight-line trends in mortality rate at each age using the spline function of Statistical Analysis Software.
Results |
Statistically significant increases in mortality rate were noted at ages 37, 60, and 78. Age was found to contribute 10% to mortality compared with greater than 80% for Glasgow coma scale and injury severity score combined.
Conclusions |
Our findings suggest using age 60 years as a data-driven definition of “elderly” in trauma.
Le texte complet de cet article est disponible en PDF.Highlights |
• | National Trauma Data Bank patients were analyzed to identify “elderly” age. |
• | We examined the association of age and mortality to identify age cut points. |
• | Three cut points were identified and age 60 years was most significant. |
• | Age 60 years is recommended to define “elderly” in trauma. |
Keywords : Elderly trauma, Geriatric trauma, Mortality, Elderly age, Age cutoff
Plan
| R.R.G. has received honoraria from LifeCell. T.M.D. has received honoraria from Pfizer and is a board member of AAST. For the remaining authors, no pharmaceutical or industry conflicts of interest were declared. |
Vol 212 - N° 4
P. 781-785 - octobre 2016 Retour au numéro
Article précédent
- Lymph node size as a simple prognostic factor in node negative colon cancer and an alternative thesis to stage migration
- Bruno Märkl, Tina Schaller, Yuriy Kokot, Katharina Endhardt, Hallie Kretsinger, Klaus Hirschbühl, Georg Aumann, Gerhard Schenkirsch
- Comparative effectiveness of treatment strategies for severe splenic trauma in the pediatric population
- Kristy L. Rialon, Brian R. Englum, Brian C. Gulack, Carlos J. Guevara, Syamal D. Bhattacharya, Mark L. Shapiro, Henry E. Rice, John E. Scarborough, Obinna O. Adibe
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?